Intensive care medicine

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

Retrieved on: 
火曜日, 5月 21, 2024
Patient, COVID-19, IMV, Food, FDA, Mortality, Tocilizumab, Conference, American Thoracic Society, MD, Hospice and palliative medicine, JAK, Risk, ATS, Intensive care medicine, Poster, Safety, Therapy, Standard of care, Pharmaceutical industry

InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET.

Key Points: 
  • InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET.
  • Tocilizumab, an anti-IL6R antibody, and baricitinib, a JAK inhibitor, are immunomodulators used in some patients as part of the standard of care treatment in this trial.
  • Day 60 all-cause mortality was 16.4% and 49.3%, respectively (HR 0.25; 95% CI:0.09-0.68, p=0.006), a significant relative reduction.
  • We believe this analysis further supports the life-saving potential of vilobelimab in the acute care setting and indicates our continued commitment to these patients.”

Pennsylvania Hospitals Become Nonprofit Joining Prime Healthcare Foundation

Retrieved on: 
月曜日, 5月 20, 2024
Philanthropy, Health, Hospitals, Practice Management, Managed Care, Foundation, General Health, EPIC, Health care, Patient, Patient safety, Patient safety organization, Hospital, Social responsibility, Prime Healthcare Services, Nurse education, Suburb, Health equity, Bernard Lown, Radiology, MD, Emergency department, Merative, Lower Bucks Hospital, IBM Watson, Intensive care medicine, Volunteering, Physician, Pharmacy, Bed

Prime Healthcare, one of the nation’s leading health systems, has initiated plans for its two Pennsylvania hospitals to become nonprofit hospitals with ownership assumed by the Prime Healthcare Foundation, a 501(c)(3) public charity.

Key Points: 
  • Prime Healthcare, one of the nation’s leading health systems, has initiated plans for its two Pennsylvania hospitals to become nonprofit hospitals with ownership assumed by the Prime Healthcare Foundation, a 501(c)(3) public charity.
  • This conversion, planned to take place in the summer of 2024, would make all Prime Healthcare hospitals in Pennsylvania nonprofit and create shared unity to address community needs under the Prime Healthcare Foundation.
  • The transaction will result in Prime Healthcare Foundation owning and operating all three Pennsylvania hospitals of Prime Healthcare, including Suburban Community Hospital in East Norriton, PA.
  • Established in 2006, the Prime Healthcare Foundation includes 14 hospitals in California, Texas, Ohio, Georgia, Pennsylvania, and Rhode Island.

EoS Fitness Kicks Off 2024 with Amplified Growth

Retrieved on: 
木曜日, 5月 16, 2024
Fitness & Nutrition, Health, Entrepreneur, Consumer, Set, HVLP, Eos, Growth, Culture, Intensive care medicine, EGYM, Perspiration, Pain

“EoS will continue this momentum in Q2 with even more new locations, exciting partnerships and some iconic EoS programs like our annual member contest Submit Your Fit.

Key Points: 
  • “EoS will continue this momentum in Q2 with even more new locations, exciting partnerships and some iconic EoS programs like our annual member contest Submit Your Fit.
  • The gym covers 42,000 square feet and is the 31st EoS Fitness location in the state.
  • Hudson, Florida : EoS Fitness' first location in the city is at 8924 State Road 52 and covers 44,000 square feet.
  • Further extending its leadership across the health and fitness industry in Q1, EoS’ Idgar was elected to the board of directors for the Health & Fitness Association (formerly IHRSA), a global community of health and fitness industry leaders.

Worldwide Point-of-Care (POC) Diagnostic Tests Market Research 2024: Focus on Prevention and Early Detection Drives Development of POC Solutions - ResearchAndMarkets.com

Retrieved on: 
木曜日, 5月 9, 2024
Health, Biotechnology, Miniaturization, Pharmacy, Pharmacist, Hospital, Nursing, Microfluidics, Emergency, History, CLIA, Operating, Patient, Physician, Caregiver, Diagnosis, POC, Test management, Intensive care medicine, Emergency medical technician, IVD, Growth, CE marking, Medical device

The geographic scope of The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024 is global, with information for specific geographical regions, world demographics, and other general issues affecting the market.

Key Points: 
  • The geographic scope of The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024 is global, with information for specific geographical regions, world demographics, and other general issues affecting the market.
  • This rich history analyzing the market is at the forefront of The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024, the eleventh edition in the publisher's POC report series.
  • The tests covered in The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024 tend to grow at higher rates than the overall IVD market.
  • The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 2024 also highlights the contribution of POC test devices to the overall diagnostics market growth.

Charting the Rise: MRI Technologies Soar with a 6.4% CAGR (2023-2028)

Retrieved on: 
金曜日, 5月 3, 2024
Conditional sentence, Cancer, Health, Ohio State University, Diabetes, Patient, Helium, MRI, BCC, Intensive care medicine, Magnetic resonance imaging, Prevalence, Ageing, Medical imaging

BOSTON, May 3, 2024 /PRNewswire/ -- According to the latest BCC Research study, the demand for Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets expected to grow from $7.2 billion in 2023 and will reach $9.8 billion by the end of 2028 at a compound annual growth rate (CAGR) of 6.4% from 2023 through 2028"

Key Points: 
  • "Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets" is a study or report that looks at MRI technology used in healthcare and its worldwide market.
  • Siemens partnered with Ohio State University to develop a new MRI tech called High-V MRI (also known as .55T).
  • Low-field MRI is a new way of doing MRI scans with machines that have much lower power than usual.
  • Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets is driven by factors such as:
    Increasing demand for advanced imaging technologies: People want better imaging tools for their health.

NSRI scientists conduct infectious aerosol risk study onboard USNS Mercy

Retrieved on: 
木曜日, 5月 2, 2024
University, SARS-CoV-2, Research, Navy, United States Navy, NSRI, Patient, USNS Comfort (T-AH-20), USS Mercy, USNS, Intensive care medicine, COVID-19, Nursing

OMAHA, Neb., May 2, 2024 /PRNewswire/ -- Scientists from the National Strategic Research Institute (NSRI) at the University of Nebraska recently spent nine days at sea on board the U.S. Navy hospital ship, USNS Mercy, to conduct testing for the underway phase of an infectious aerosol risk study.

Key Points: 
  • OMAHA, Neb., May 2, 2024 /PRNewswire/ -- Scientists from the National Strategic Research Institute (NSRI) at the University of Nebraska recently spent nine days at sea on board the U.S. Navy hospital ship, USNS Mercy, to conduct testing for the underway phase of an infectious aerosol risk study.
  • MERCY's secondary mission is to provide full hospital services to support U.S. disaster relief and humanitarian operations worldwide.
  • During the COVID-19 pandemic, the USNS Mercy and its sister hospital ship, USNS Comfort, deployed to Los Angeles and New York City, respectively.
  • The study aims to identify risks associated with infectious airborne pathogens, including SARS-CoV-2, so decision makers can implement strategies to mitigate risks and ensure operational readiness and mission success.

EQS-News: Lindis Blood Care Announces Positive Top-Line Results from Clinical Certification Study REMOVE with CATUVAB® to Enable Autologous Blood Transfusions in Cancer Surgeries

Retrieved on: 
金曜日, 5月 3, 2024
FDA, Cancer, Prostate, Cell, Risk, Blood, Filter, CE marking, Cytokine, Trauma, Immunosuppression, Intensive care medicine, MD, Carcinoma, PILOT, Pain management, Patient, Lung, Teaching hospital, Clinical trial, IBS, Medical imaging

Convincing safety profile supports use of CATUVAB® during high blood loss cancer surgeries.

Key Points: 
  • Convincing safety profile supports use of CATUVAB® during high blood loss cancer surgeries.
  • Following these positive results, Company has initiated process to receive CE Mark in Europe and FDA conformity in the US.
  • Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, announced today excellent top-line results from the REMOVE certification study, a confirmatory open-label, multicenter clinical study, that enrolled more than 130 patients to assess CATUVAB® for use during intraoperative blood salvage (IBS) procedures in cancer surgeries.
  • CATUVAB® is designed to reliably remove cells from EpCAM (epithelial cell adhesion molecule)-positive tumors from the blood of cancer patients.

EQS-News: Lindis Blood Care to Present Top Line Results from Clinical Certification Study REMOVE with CATUVAB® at NATA24 Annual Symposium

Retrieved on: 
金曜日, 5月 3, 2024
Cancer, Safety, Blood, Immunosuppression, Intensive care medicine, Pain management, Patient, Teaching hospital, Lymphocyte, IBS, Medical device

Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.

Key Points: 
  • Lindis Blood Care, a company aiming to set a new standard for blood management during cancer surgeries with its medical device CATUVAB®, today announces that top line results of its certification study REMOVE assessing the Company’s medical device for the removal of tumor cells from intraoperative blood during high-blood loss surgeries will be presented at the NATA24 Annual Symposium.
  • The symposium will take place in Bologna, Italy between April 18 – 20, 2024.
  • CATUVAB® aims to ensure that cancer patients receive their own blood, minimizing the risks associated with allogenic (donor) blood transfusions.
  • Following the positive study outcome, CATUVAB® is aimed for approval in the EU and US in accordance with Medical Device Regulations.

Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
月曜日, 4月 15, 2024
Sale, Idiopathic pulmonary fibrosis, Weill Cornell Medicine, University, Internal, Research and development, Epithelium, Investment, Fibroblast, Interstitial, Pleural effusion, IPF, LPE, Intensive care medicine, Administration, University of Giessen, University of Alabama, Patient, Acquisition, Fibrosis, Associate, Series, Therapy, G&A, Critical Care Medicine (journal), ALRN, Pharmaceutical industry

AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.

Key Points: 
  • We expect to report topline results from the ongoing Phase 1b study of LTI-03 in the third quarter of this year.
  • Net Loss: Net loss for the quarter ended December 31, 2023, was $7.3 million, compared to $4.5 million for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the quarter ended December 31, 2023 was $1.54 compared to $1.00 for the quarter ended December 31, 2022.
  • The basic and diluted net loss per share for the full-year 2023 was $3.42 compared to $6.02 for the full-year 2022.

Liberate Medical Announces PREVENT Study with $6.5M Grant Funding from the US DoD – Enrolls First Patients Globally

Retrieved on: 
火曜日, 4月 30, 2024
Technology, Research, Medical Devices, FDA, Clinical Trials, Hardware, Health, General Health, Science, University, Radboud University Medical Center, Risk, Fungal infection, Death, Cough, Intensive care medicine, ICU, European, Patient, Acquisition, PI, Assistant, Quality of life, Baylor University, Critical Care Medicine (journal), CE

Reducing the time patients spend on mechanical ventilation should reduce the risks of prolonged mechanical ventilation, including hospital-acquired infections, deteriorated quality of life and death.

Key Points: 
  • Reducing the time patients spend on mechanical ventilation should reduce the risks of prolonged mechanical ventilation, including hospital-acquired infections, deteriorated quality of life and death.
  • PREVENT is a global collaborative effort that plans to enroll 272 patients from 25 centers across the US, EU and Australia.
  • Liberate Medical extends its deepest gratitude and congratulations to these institutions for their commitment and swift implementation of the PREVENT study.
  • "The initiation of patient enrollment in the PREVENT trial is a landmark event for Liberate Medical and innovation in critical care medicine.